2022 World Conference on Lung Cancer (ePosters)-EP08.02-083. Real World Treatment and Outcomes in EGFR-mutated Advanced Non-small Cell Lung Cancer Patients: A Nationwide Cohort for 1,932 Thai Patients

EP08.02-083. Real World Treatment and Outcomes in EGFR-mutated Advanced Non-small Cell Lung Cancer Patients: A Nationwide Cohort for 1,932 Thai Patients

Back to course

Pdf Summary

A nationwide cohort study in Thailand analyzed the characteristics and outcomes of 1,932 patients with advanced non-small cell lung cancer (NSCLC) who had epidermal growth factor receptor (EGFR) mutations and received gefitinib treatment between January 2018 and December 2020. The study aimed to provide real-world data on the treatment and outcomes of patients with EGFR-mutated NSCLC in Thailand. <br /><br />The study found that the patient demographics and outcomes were generally consistent with randomized phase III trials. The use of EGFR tyrosine kinase inhibitors (TKIs) showed benefits for EGFR-mutated NSCLC patients in all lines of treatment. However, further real-world studies are needed to determine the outcomes of emerging therapies or rare subgroups of NSCLC patients outside of clinical trial settings.<br /><br />The majority of patients in the study had metastatic disease, with 73.1% having metastasis at more than two sites. Brain metastasis was observed in 13.4% of patients. The study also identified prognostic factors for progression-free survival (PFS), including age over 70 years, poor performance status, presence of liver and bone metastasis, non-adenocarcinoma histology, and specific EGFR mutations (L858R).<br /><br />The median PFS for first-, second-, and later-line treatments were 11.2 months, 11.6 months, and 14.5 months, respectively. Patients with exon 19 del and L858R mutations had median PFS of 11.5 months and 10.8 months, respectively. The overall response rate (ORR) and disease control rate (DCR) were 48.5% and 72.8%, respectively, and did not differ across treatment lines.<br /><br />In conclusion, this real-world study provides valuable insight into the treatment and outcomes of Thai patients with advanced EGFR-mutated NSCLC receiving gefitinib. The findings support the use of EGFR TKIs as a standard of care in this patient population and highlight the importance of considering specific prognostic factors when determining treatment approaches. Further research is needed to assess the effectiveness of emerging therapies and rare subgroups of NSCLC patients in real-world settings.

Asset Subtitle

Kakanan Tienchai

Meta Tag

Speaker Kakanan Tienchai

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

nationwide cohort study

Thailand

advanced non-small cell lung cancer

EGFR mutations

gefitinib treatment

real-world data

prognostic factors

progression-free survival

EGFR TKIs

treatment outcomes